%0 Journal Article
%T PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer
%A Amr S Khaled
%A Annette R. Khaled
%A Charalambos Kaittanis
%A J Manuel Perez
%A Jan Grimm
%A Orielyz Flores
%A Rania Bassiouni
%A Santimukul Santra
%J Theranostics
%D 2017
%I Ivyspring International Publisher
%R 10.7150/thno.18879
%X Herein, we report the use of a theranostic nanocarrier (Folate-HBPE(CT20p)) to deliver a therapeutic peptide to prostate cancer tumors that express PSMA (folate hydrolase 1). The therapeutic peptide (CT20p) targets and inhibits the chaperonin-containing TCP-1 (CCT) protein-folding complex, is selectively cytotoxic to cancer cells, and is non-toxic to normal tissue. With the delivery of CT20p to prostate cancer cells via PSMA, a dual level of cancer specificity is achieved: (1) selective targeting to PSMA-expressing prostate tumors, and (2) specific cytotoxicity to cancer cells with minimal toxicity to normal cells. The PSMA-targeting theranostic nanocarrier can image PSMA-expressing cells and tumors when a near infrared dye is used as cargo. Meanwhile, it can be used to treat PSMA-expressing tumors when a therapeutic, such as the CT20p peptide, is encapsulated within the nanocarrier. Even when these PSMA-targeting nanocarriers are taken up by macrophages, minimal cell death is observed in these cells, in contrast with doxorubicin-based therapeutics that result in significant macrophage death. Incubation of PSMA-expressing prostate cancer cells with the Folate-HBPE(CT20p) nanocarriers induces considerable changes in cell morphology, reduction in the levels of integrin ¦Â1, and lower cell adhesion, eventually resulting in cell death. These results are relevant as integrin ¦Â1 plays a key role in prostate cancer invasion and metastatic potential. In addition, the use of the developed PSMA-targeting nanocarrier facilitates the selective in vivo delivery of CT20p to PSMA-positive tumor, inducing significant reduction in tumor size.
%K polymeric nanoparticles
%K peptide
%K PSMA
%K prostate cancer.
%U http://www.thno.org/v07p2477.htm